search
Back to results

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Primary Purpose

Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis

Status
Recruiting
Phase
Phase 1
Locations
Sweden
Study Type
Interventional
Intervention
C106 solution
Placebo
Sponsored by
Vicore Pharma AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Safety Issues

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Willing and able to give written informed consent for participation in the trial.
  2. Healthy males and females of non-childbearing potential aged 18-65 years inclusive.
  3. Body Mass Index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2
  4. Clinically normal medical history, physical findings, vital signs, ECG, and laboratory values at the time of screening, as judged by the Investigator
  5. Women of non-childbearing potential, defined as pre-menopausal females who are sterilized (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with simultaneous detection of follicle stimulating hormone [FSH] ≥ 25 IU/L is confirmatory).

Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after (last) dosing with the IMP. Their female partner of child-bearing potential must use highly effective contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD]or intrauterine hormone-releasing system [IUS]) from at least 4 weeks prior to dose to 3 months after last dose.

Exclusion Criteria:

  1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the trial, or influence the results or the subject's ability to participate in the trial.
  2. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  3. Malignancy within the past 5 years except for in situ removal of basal cell carcinoma.
  4. Any planned major surgery within the duration of the trial.
  5. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV).
  6. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:

    • Systolic blood pressure <90 or >140 mmHg, or
    • Diastolic blood pressure <50 or >90 mmHg, or
    • Pulse <40 or >90 bpm
  7. Prolonged QTcF (>450 ms), PR interval < 120 ms or > 240 ms, QRS>115 ms, clinically significant cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
  8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to C106.
  9. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
  10. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. Subjects consented and screened but not dosed in previous clinical trials are not excluded.
  11. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
  12. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP.
  13. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
  14. Presence or history of drug abuse, as judged by the Investigator.
  15. History of, or current use of, anabolic steroids.
  16. Excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages.
  17. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
  18. Investigator considers the subject unlikely to comply with trial procedures, restrictions, and requirements.

Sites / Locations

  • CTC Clinical Trial Consultants ABRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

C106 solution

Placebo

Arm Description

Part A: Oral administration start dose, Single dose 5 mg Part B: Oral administration start dose 20 mg twice daily for 8 days

Part A and B: Placebo to C106 without the active pharmaceutical ingredient

Outcomes

Primary Outcome Measures

Treatment Emergent adverse events (AEs) and serious AEs (SAEs)
AE reporting and questioning. AEs must be recorded in the AE Log of the eCRF. The Investigator must provide information on the AE, preferably with a diagnosis or at least with signs and symptoms; start and stop dates, start and stop time; intensity; causal relationship to IMP; action taken, and outcome. If the AE is serious, this must be indicated in the eCRF. AEs, including out-of-range clinically significant clinical safety laboratory values, must be recorded individually, except when considered manifestations of the same medical condition or disease state; in such cases, they must be recorded under a single diagnosis.
Number of reported clinically significant changes from baseline in 12-lead electrocardiograms (ECGs)
Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. Abnormalities will be specified and documented as clinically significant or not clinically significant
Clinically significant changes in vital signs, systolic and diastolic blood pressure
Will be measured in supine position after 10 minutes of rest.
Clinically significant changes in vital signs, pulse
Will be measured in supine position after 10 minutes of rest.
Clinically significant changes in vital signs, respiratory rate
Will be assessed in supine position after 10 minutes of rest.
Clinically significant changes in vital signs, temperature
Measured with digital thermometer
Number of subjects with abnormal and clinically significant safety laboratory test results post-dose
Any lab values outside the normal ranges will be judged as not clinically significant or clinically significant. Abnormal post-dose findings assessed by the Investigator as clinically significant will be reported as AEs. Laboratory Safety variables are (haematology, coagulation, clinical chemistry and urine analysis
Number of subjects with abnormal and significant physical examination findings post-dose
Any abnormalities will be specified and documented as clinically significant or not clinically significant. Abnormal post-dose findings assessed by the Investigator as clinically significant will be reported as AEs. A complete physical examination will include assessments of the head, eyes, ears, nose, throat, skin, neurological, lungs, cardiovascular, and abdomen

Secondary Outcome Measures

Measurement of the PK profile (Cmax)
To assess the maximum Plasma Concentration (Cmax)
Measurement of the PK profile (t1/2)
To assess the plasma half life (t1/2) of the drug
Measurement of the PK profile (total clearance)
To assess the total clearance of the drug
Measurement of PK profile (dose proportionality)
To assess the dose proportionality of the drug
Measure % of dose excreted unchanged in urine of single and multiple oral doses of C106 of healthy subjects.
PK sampling in urine in Part A and B.
To evaluate the effect of a high fat meal on the single oral dose PK of C106 in healthy subjects (Part A) by relative bioavailibity of C106 in fasted versus fed conditions.
PK sampling in plasma and urine after single oral doses of C106 in healthy subjects, PK parameters as for Part A.
Investigate Renal Clearance in Part A and B of single and multiple oral doses of C106 of healthy subjects.
PK sampling in blood and urine
Identify accumulation ratios (based on AUCtau and Cmax)
PK sampling in blood and urine after multiple oral doses of C106 in healthy subjects.
Evaluate the observed concentration at the end of a dosing interval, immediately before next administration (Ctrough)
PK sampling in blood and urine after multiple doses of C106 in healthy subjects

Full Information

First Posted
June 7, 2022
Last Updated
March 24, 2023
Sponsor
Vicore Pharma AB
search

1. Study Identification

Unique Protocol Identification Number
NCT05427253
Brief Title
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Official Title
A Double-blind, Placebo-controlled, Randomised, First in Human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of C106 in Healthy Male and Female Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 15, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
July 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vicore Pharma AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in healthy females of non-childbearing potential and healthy males. The trial will be conducted in 2 parts: Part A, single ascending dose (SAD) including a food interaction cohort: safety, tolerability, and PK in healthy males and healthy females of non-childbearing potential receiving single ascending doses of C106. Part B, multiple ascending dose (MAD): safety, tolerability, and PK in healthy males and healthy females of non-childbearing potential receiving twice daily multiple ascending doses of C106 for 8 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Part A, single ascending dose (SAD) including a food interaction cohort Part B, multiple ascending dose (MAD)
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The IMP, i.e., the C106 and the placebo oral solutions, are identical in appearance. Both solutions are colourless to yellow. Hence, it is expected that the subjects, Investigator and other site personnel will remain unaware of treatment allocation.
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
C106 solution
Arm Type
Experimental
Arm Description
Part A: Oral administration start dose, Single dose 5 mg Part B: Oral administration start dose 20 mg twice daily for 8 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Part A and B: Placebo to C106 without the active pharmaceutical ingredient
Intervention Type
Drug
Intervention Name(s)
C106 solution
Intervention Description
selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for C106 solution
Primary Outcome Measure Information:
Title
Treatment Emergent adverse events (AEs) and serious AEs (SAEs)
Description
AE reporting and questioning. AEs must be recorded in the AE Log of the eCRF. The Investigator must provide information on the AE, preferably with a diagnosis or at least with signs and symptoms; start and stop dates, start and stop time; intensity; causal relationship to IMP; action taken, and outcome. If the AE is serious, this must be indicated in the eCRF. AEs, including out-of-range clinically significant clinical safety laboratory values, must be recorded individually, except when considered manifestations of the same medical condition or disease state; in such cases, they must be recorded under a single diagnosis.
Time Frame
From date of signing informed consent until End of Study, assessed up to Day 22
Title
Number of reported clinically significant changes from baseline in 12-lead electrocardiograms (ECGs)
Description
Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. Abnormalities will be specified and documented as clinically significant or not clinically significant
Time Frame
Part A: Up to Day 10. Part B: Up to Day 22.
Title
Clinically significant changes in vital signs, systolic and diastolic blood pressure
Description
Will be measured in supine position after 10 minutes of rest.
Time Frame
Part A: Up to Day 3, Part B: Up to Day 10
Title
Clinically significant changes in vital signs, pulse
Description
Will be measured in supine position after 10 minutes of rest.
Time Frame
Part A: Up to Day 3, Part B: Up to Day 10
Title
Clinically significant changes in vital signs, respiratory rate
Description
Will be assessed in supine position after 10 minutes of rest.
Time Frame
Part A:Up Day 3, Part B: Up to Day 10
Title
Clinically significant changes in vital signs, temperature
Description
Measured with digital thermometer
Time Frame
Part A:Up Day 3, Part B: Up to Day 10
Title
Number of subjects with abnormal and clinically significant safety laboratory test results post-dose
Description
Any lab values outside the normal ranges will be judged as not clinically significant or clinically significant. Abnormal post-dose findings assessed by the Investigator as clinically significant will be reported as AEs. Laboratory Safety variables are (haematology, coagulation, clinical chemistry and urine analysis
Time Frame
Part A: Up to Day 3, Part B: Up to Day 10
Title
Number of subjects with abnormal and significant physical examination findings post-dose
Description
Any abnormalities will be specified and documented as clinically significant or not clinically significant. Abnormal post-dose findings assessed by the Investigator as clinically significant will be reported as AEs. A complete physical examination will include assessments of the head, eyes, ears, nose, throat, skin, neurological, lungs, cardiovascular, and abdomen
Time Frame
Part A: Day 7, Part B: Day 22
Secondary Outcome Measure Information:
Title
Measurement of the PK profile (Cmax)
Description
To assess the maximum Plasma Concentration (Cmax)
Time Frame
Part A up to Day 3, Part B up to Day 10
Title
Measurement of the PK profile (t1/2)
Description
To assess the plasma half life (t1/2) of the drug
Time Frame
Up to Day 3
Title
Measurement of the PK profile (total clearance)
Description
To assess the total clearance of the drug
Time Frame
Up to Day 3
Title
Measurement of PK profile (dose proportionality)
Description
To assess the dose proportionality of the drug
Time Frame
Part A: Up to Day 3, Part B: Up to Day 10
Title
Measure % of dose excreted unchanged in urine of single and multiple oral doses of C106 of healthy subjects.
Description
PK sampling in urine in Part A and B.
Time Frame
Part A: Up to Day 3, Part B: Up to Day 10
Title
To evaluate the effect of a high fat meal on the single oral dose PK of C106 in healthy subjects (Part A) by relative bioavailibity of C106 in fasted versus fed conditions.
Description
PK sampling in plasma and urine after single oral doses of C106 in healthy subjects, PK parameters as for Part A.
Time Frame
Up to Day 3
Title
Investigate Renal Clearance in Part A and B of single and multiple oral doses of C106 of healthy subjects.
Description
PK sampling in blood and urine
Time Frame
Part A: Up to Day 3 Part B: Up to 8
Title
Identify accumulation ratios (based on AUCtau and Cmax)
Description
PK sampling in blood and urine after multiple oral doses of C106 in healthy subjects.
Time Frame
Up to Day 10
Title
Evaluate the observed concentration at the end of a dosing interval, immediately before next administration (Ctrough)
Description
PK sampling in blood and urine after multiple doses of C106 in healthy subjects
Time Frame
Up to Day 10
Other Pre-specified Outcome Measures:
Title
Evaluate the metabolite profile of C106 in plasma of healthy subjects at steady state (Part B).
Description
Metabolite In Safety Testing (MIST) analysis of the metabolite profile in plasma in comparison with the metabolite profile in plasma from non-clinical safety studies. Blood sampling for future analysis of C106 metabolites will be performed at steady state in Part B (MAD), i.e., from Day 8 The same samples constitute an aliquot of separated plasma (750 µL) generated from each PK sample
Time Frame
Day 8
Title
To estimate the excreted C106 and its metabolites and the metabolite profile of C106 in urine of healthy subjects at steady state (Part B).
Description
Urine sampling (an aliquot of 5 mL urine taken from the PK urine samples) for future analysis of excreted C106 metabolites in the urine.
Time Frame
Up to Day 8
Title
To collect and store ECG data for potential future evaluation of the effect of C106 on ECG parameters, including concentration-QTc analysis using Expert Precision QT (EPQT) assessment (Part A).
Description
Continuous ECG recordings will be performed for 25 hours, starting 1 hour prior to dose administration and baseline ECGs will be extracted at 3 time points before dosing (-45, -30 and -15 minutes).
Time Frame
25 hours, starting 1 hour pre-dose day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Willing and able to give written informed consent for participation in the trial. Healthy males and females of non-childbearing potential aged 18-65 years inclusive. Body Mass Index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 Clinically normal medical history, physical findings, vital signs, ECG, and laboratory values at the time of screening, as judged by the Investigator Women of non-childbearing potential, defined as pre-menopausal females who are sterilized (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with simultaneous detection of follicle stimulating hormone [FSH] ≥ 25 IU/L is confirmatory). Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after (last) dosing with the IMP. Their female partner of child-bearing potential must use highly effective contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD]or intrauterine hormone-releasing system [IUS]) from at least 4 weeks prior to dose to 3 months after last dose. Exclusion Criteria: History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the trial, or influence the results or the subject's ability to participate in the trial. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP. Malignancy within the past 5 years except for in situ removal of basal cell carcinoma. Any planned major surgery within the duration of the trial. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV). After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges: Systolic blood pressure <90 or >140 mmHg, or Diastolic blood pressure <50 or >90 mmHg, or Pulse <40 or >90 bpm Prolonged QTcF (>450 ms), PR interval < 120 ms or > 240 ms, QRS>115 ms, clinically significant cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to C106. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. Subjects consented and screened but not dosed in previous clinical trials are not excluded. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator. Presence or history of drug abuse, as judged by the Investigator. History of, or current use of, anabolic steroids. Excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening. Investigator considers the subject unlikely to comply with trial procedures, restrictions, and requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cecilia Ganslandt, MD, MSc
Phone
+46 (0)705 797 075
Email
cecilia.ganslandt@vicorepharma.com
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Katrine Cohrt, MSc
Phone
+ 45 2011 1391
Email
anne-katrine.cohrt@vicorepharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Måns Jergil, PhD
Organizational Affiliation
CTC Clinical Trial Consultants AB (CTC)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Helena Litorp, MD, PhD
Organizational Affiliation
CTC Clinical Trial Consultants AB (CTC)
Official's Role
Principal Investigator
Facility Information:
Facility Name
CTC Clinical Trial Consultants AB
City
Uppsala
ZIP/Postal Code
SE-752 37
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helena Litorp, MD PhD
Phone
+4618303300
Email
helena.litorp@ctc-ab.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

We'll reach out to this number within 24 hrs